NASDAQ
87.64USD
+18.66 (+27.05%)
We have scored 29 news catalysts on TransMedics Group, Inc. (TMDX) over the past 12 months. The biggest single-day move next to one of them came Aug 5, 2026, when TMDX closed −5.3%: “ALAR Investors Have Opportunity to Lead Alarum Technologies Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm”. Coverage across the window leans positive (average ticker sentiment +0.24). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
3B
P/E
—
EPS
—
Beta
2.10
52W range
60.105-156
Day range
76.50–87.88
Open
78.71
Prev close
68.98
Volume
1.8M
Avg volume
857.9K
Dividend
0.00
IPO
2019-05-02
Analysts publish price targets on TMDX, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $65 to $122
as of 2026-09-24
The market is within 3% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about TransMedics Group, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for TMDX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
The price sits within 3% of the median published target, meaning the market broadly agrees with the middle view and has firmly rejected both the 40% upside of the bull case and the 25% downside of the bear case.
What the disagreement turns on
Whether the company's heavy investments in logistics and the new kidney program can actually re-accelerate growth and expand margins toward 30% by 2028, or whether those investments just weigh on profitability while growth continues to decelerate; unit volume data can track the growth, but nothing wired can settle the margin or legal questions.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
